FDA Approves Belzutifan for Pheochromocytoma or Paraganglioma By Ogkologos - June 6, 2025 469 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LITESPARK-015 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Drug Combo JAKs Up Immunotherapy in Two Clinical Trials August 8, 2024 BREAKING: President Trump May Restore The WHO’s Funding, With Some Conditions May 18, 2020 When You Have Cancer and You’re a Parent: “Your Stories” Podcast February 17, 2021 Enfortumab Vedotin Approved for Recurrent Bladder Cancer January 14, 2020 Load more HOT NEWS EMA Recommends Extension of Therapeutic Indications for Acalabrutinib Scientists Focus on Fusion Proteins in Childhood Cancers Obesity May Help Tumors Survive and Grow, Mouse Study Suggests How cancer hijacks cell death: a new view of metastasis
